Antiparasitic Therapy - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Antiparasitic Therapy

The Experts below are selected from a list of 1035 Experts worldwide ranked by ideXlab platform

Antiparasitic Therapy – Free Register to Access Experts & Abstracts

Mahendra Bhandari – One of the best experts on this subject based on the ideXlab platform.

  • Visceral Leishmaniasis in a Renal Transplant Recipient: Diagnostic and Therapeutic Problems
    American journal of nephrology, 1996
    Co-Authors: Raj K. Sharma, Ratan Jha, Pradeep Kumar, Vijay Kher, Amit Gupta, Anant Kumar, Sanjeev Gulati, Pradeep Arora, Manjula Murari, Mahendra Bhandari

    Abstract:

    Visceral leishmaniasis is infrequently reported in renal transplant recipients. A 40-year-old renal transplant recipient developed hepatosplenomegaly and pyrexia of unknown origin 5 months after transplantation. Visceral leishmaniasis was confirmed on bone marrow examination. The usual dose of Antiparasitic Therapy with stibogluconate sodium failed to eradicate Leishmania donovani. High-dose conventional Therapy with stibogluconate sodium for an extended period of time was successful in the treatment of a relapse of leishmaniasis.

Brian G. Blackburn – One of the best experts on this subject based on the ideXlab platform.

  • SYMPOSIUM ON ANTIMICROBIAL TherapyAntiparasitic Therapy
    Mayo Clinic proceedings, 2011
    Co-Authors: Shanthi Kappagoda, Upinder Singh, Brian G. Blackburn

    Abstract:

    Parasitic diseases affect more than 2 billion people globally and cause substantial morbidity and mortality, particularly among the world’s poorest people. This overview focuses on the treatment of the major protozoan and helminth infections in humans. Recent developments in Antiparasitic Therapy include the expansion of artemisinin-based therapies for malaria, new drugs for soil-transmitted helminths and intestinal protozoa, expansion of the indications for Antiparasitic drug treatment in patients with Chagas disease, and the use of combination Therapy for leishmaniasis and human African trypanosomiasis.

Tomasz Kula – One of the best experts on this subject based on the ideXlab platform.

  • Endobiont Viruses Sensed by the Human Host – Beyond Conventional Antiparasitic Therapy
    PloS one, 2012
    Co-Authors: Raina N. Fichorova, Yujin Lee, Hidemi S. Yamamoto, Yuko Takagi, Gary R. Hayes, Russell P. Goodman, Xenia Chepa-lotrea, Olivia R. Buck, Richard Murray, Tomasz Kula

    Abstract:

    Wide-spread protozoan parasites carry endosymbiotic dsRNA viruses with uncharted implications to the human host. Among them, Trichomonas vaginalis, a parasite adapted to the human genitourinary tract, infects globally ∼250 million each year rendering them more susceptible to devastating pregnancy complications (especially preterm birth), HIV infection and HPV-related cancer. While first-line antibiotic treatment (metronidazole) commonly kills the protozoan pathogen, it fails to improve reproductive outcome. We show that endosymbiotic Trichomonasvirus, highly prevalent in T. vaginalis clinical isolates, is sensed by the human epithelial cells via Toll-like receptor 3, triggering Interferon Regulating Factor -3, interferon type I and proinflammatory cascades previously implicated in preterm birth and HIV-1 susceptibility. Metronidazole treatment amplified these proinflammatory responses. Thus, a new paradigm targeting the protozoan viruses along with the protozoan host may prevent trichomoniasis-attributable inflammatory sequelae.

  • endobiont viruses sensed by the human host beyond conventional Antiparasitic Therapy
    PLOS ONE, 2012
    Co-Authors: Raina N. Fichorova, Yujin Lee, Hidemi S. Yamamoto, Yuko Takagi, Gary R. Hayes, Russell P. Goodman, Olivia R. Buck, Xenia Chepalotrea, Ryan Murray, Tomasz Kula

    Abstract:

    Wide-spread protozoan parasites carry endosymbiotic dsRNA viruses with uncharted implications to the human host. Among them, Trichomonas vaginalis, a parasite adapted to the human genitourinary tract, infects globally ∼250 million each year rendering them more susceptible to devastating pregnancy complications (especially preterm birth), HIV infection and HPV-related cancer. While first-line antibiotic treatment (metronidazole) commonly kills the protozoan pathogen, it fails to improve reproductive outcome. We show that endosymbiotic Trichomonasvirus, highly prevalent in T. vaginalis clinical isolates, is sensed by the human epithelial cells via Toll-like receptor 3, triggering Interferon Regulating Factor -3, interferon type I and proinflammatory cascades previously implicated in preterm birth and HIV-1 susceptibility. Metronidazole treatment amplified these proinflammatory responses. Thus, a new paradigm targeting the protozoan viruses along with the protozoan host may prevent trichomoniasis-attributable inflammatory sequelae.